Systematic review on reducing missed opportunities for vaccinations in Latin America

Malavika Tampi,1 Alonso Carrasco-Labra,2 Kelly K. O'Brien,3 Martha Velandia-González,4 and Romina Brignardello-Petersen5

Suggested citation Tampi M, Carrasco-Labra A, O'Brien KK, Velandia-González M, Brignardello-Petersen R. Systematic review on reducing missed opportunities for vaccinations in Latin America. Rev Panam Salud Publica. 2022;46:e65. https://doi.org/10.26633/RPSP.2022.65

ABSTRACT Objectives. To estimate the prevalence of missed opportunities for vaccination (MOV) in Latin America and the effect of interventions targeting health systems, health workers, patients, and communities on MOV.

Methods. Searches were conducted in MEDLINE, EMBASE, CINAHL, and LILACS electronic databases and relevant organizations were contacted, including the Pan American Health Organization (PAHO), to identify studies meeting eligibility criteria. A pair of reviewers identified 27 randomized and non-randomized studies quantifying the effectiveness of any intervention for reducing MOV and 5 studies assessing the rate of MOV in Latin America. Results are reported narratively when criteria to pool results were not met, and the certainty of this evidence was assessed using the GRADE approach.

Results. Evidence suggests the rate of MOV in Latin America ranged from 5% to 37% with a pooled estimate of 17% (95% CI [9, 32]) (low certainty) and that monetary incentives to healthcare teams, training for healthcare teams on how to communicate with patients, and educational interventions for caregivers probably reduce MOV (moderate to very low certainty).

Conclusions. There is insufficient evidence supporting the implementation of any intervention as policy based only on the potential reduction of MOV without considering several factors, including costs, feasibility, acceptability, and equity.

Keywords Vaccination; vaccination coverage; immunization; Latin America.

Immunization is a process by which a person becomes immune or resistant to an infectious disease (1). Vaccinations are a well-studied tool for achieving immunization and avert approximately 3 million deaths per year globally. For example, vaccination programs, like the Expanded Program on Immunization (EPI), prevented approximately 174 000 deaths of children between 2006 and 2011 (2, 3). Strong evidence suggests vaccination prevents morbidity and mortality from diseases such as diphtheria, measles, pertussis, pneumonia, polio, rotavirus diarrhea, rubella, and tetanus, as well as cancers such as liver and cervical cancer (4). Additionally, vaccines are often safer than therapeutic measures and can eradicate diseases in specific communities if up to 95% of the population achieves complete immunization (4). For example, the Region of the Americas (the Region) has eliminated smallpox (in 1971), poliomyelitis (1994), rubella and congenital rubella syndrome...

1 University of Michigan School of Dentistry, Ann Arbor, Michigan, United States of America
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
3 American Dental Association, Chicago, Illinois, United States of America
4 Pan American Health Organization, Washington, D.C., United States of America
5 McMaster University, Hamilton, Ontario, Canada

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. No modifications or commercial use of this article are permitted. In any reproduction of this article there should not be any suggestion that PAHO or this article endorse any specific organization or products. The use of the PAHO logo is not permitted. This notice should be preserved along with the article's original URL. Open access logo and text by PLoS, under the Creative Commons Attribution-Share Alike 3.0 Unported license.
(2015), and measles (2016) through immunization (5, 6). Immunization can also contribute to considerable cost-savings for health systems (4). Despite this, many children and adults are still affected by vaccine-preventable diseases. Estimates from the World Health Organization (WHO) suggest that approximately 6.9 million children died from vaccine-preventable diseases in 2011, while approximately 22.6 million infants were not provided essential vaccines (2).

Immunization schedules and vaccine coverage vary nationally and internationally. For example, coverage in Latin America and the Caribbean has considerably decreased since 2013, less than half of countries in the Region reached the WHO 90% coverage target in 2017, and coverage continues to vary dramatically between countries in the Region (3). Due to the COVID-19 pandemic, recent declines in vaccine coverage have the potential to erode historic and hard-fought gains in the Region. A comparison of the number of children receiving diphtheria–tetanus–pertussis (DTP3) and measles, mumps, and rubella (MMR) vaccinations from January to June of 2019 and 2020, respectively, indicates that vaccination coverage decreased by 33% for DPT3 and by 24% for MMR in the Region (7). A number of challenges impede vaccination coverage in the Region, including hard-to-reach communities, political instability, unfavorable socioeconomic factors, religious/cultural beliefs, vaccine hesitancy, limited resources, poor management of health systems, and inadequate monitoring and supervision (2, 8–10).

WHO recommends that immunization should be offered to all eligible individuals at every contact point with health services (3, 11). When it is not offered, this is referred to as a “missed opportunity for vaccination” (MOV). An earlier review identified four main reasons for missed opportunities: 1) failure to simultaneously administer all vaccines for an eligible child; 2) false contraindications to immunization; 3) health worker practices; and 4) logistical problems (11). Though patients may seek immunization services, healthcare systems may not accommodate these requests due to lack of an appointment, immunization not being the primary reason for the visit, and despite there being no health-related contraindications. Additionally, patients may seek care in health facilities where immunization is simply not offered (12).

Research has identified several potential approaches (e.g., one-on-one coaching with caregivers) to reduce MOVs (13). Interventions aimed at reducing MOVs are likely to increase vaccination coverage and therefore magnify all beneficial downstream consequences associated with immunization.

Preexisting reviews have identified the main reasons for low vaccine coverage and MOVs (11, 14, 15). Additionally, an earlier systematic review included evidence from randomized controlled trials (RCTs) to measure the effect of interventions on MOVs (13). Although RCTs are the ideal study design for comparing effects of interventions, utilizing evidence from non-randomized studies can provide a comprehensive summary of all evidence on benefits and harms (16). Additionally, previously published reviews have not adequately assessed the certainty of, or confidence in, included evidence.

Regional decisionmakers have called for a comparison of interventions for reducing MOVs (Objective 1) and a summary of evidence (published by national and international organizations) on the rate, or prevalence, of MOVs in Latin America (Objective 2) to comprehensively inform regional decisionmakers on the magnitude of MOVs and potential strategies for reducing these.

MATERIALS AND METHODS

This report is primarily an update of another review—an internal, unpublished systematic review for the Pan American Health Organization (PAHO)—developed in response to a call for evidence on interventions to reduce MOVs. In this update, we included randomized and non-randomized studies on interventions for reducing MOVs (Objective 1). For this current review, we also summarized results from studies measuring the rate of MOVs in Latin America (Objective 2). Reporting of this systematic review was informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and conducted according to a protocol approved by PAHO (available upon request) (17).

Study eligibility

Interventions for reducing MOVs (Objective 1). We included studies on interventions for reducing MOVs for immunizations recommended by WHO with a particular focus on vaccination of the following populations: children under 5 years of age, women of childbearing age, and older adults. We did not include immunizations for human papillomavirus (HPV) due to inconsistent inclusion of HPV vaccination in immunization schedules within the Region (18).

We included RCTs, quasi-randomized controlled trials (CCTs), controlled before-and-after studies (CBAs), and interrupted time series (ITS) quantifying the effect of any intervention (of any duration and in any setting) used for reducing MOVs. We included studies in any language published after 1990. We categorized the interventions as follows:

- Interventions targeting the health system including changes in organization of care within a particular healthcare setting;
- Interventions targeting health workers including hospital administrators, clinicians, nurses, and any other individuals involved in the immunization process;
- Interventions targeting patients or community members including children, adults, caregivers or parents, women of childbearing age, and older adults;
- Mixed interventions targeting one or more of the above categories.

We included studies that compared interventions to another intervention or no intervention, or where the same intervention was monitored over time.

Outcomes of interest. We summarized the following outcomes from included studies:

MOVs defined as any healthcare visit that did not result in participants of any age receiving the needed vaccine (11). MOVs were further classified as:

a. Attributable to the healthcare system;
b. Attributable to the knowledge, attitudes, and/or decisions of individual patients, caregivers, etc.;
c. Attributable to the knowledge and/or attitudes of healthcare personnel.
Rate of MOVs in Latin America (Objective 2). We included any report or study on the rate, or prevalence, of MOVs in Latin America that followed PAHO methodology (19).

Search strategy

Interventions for reducing MOVs (Objective 1). We searched the MEDLINE, EMBASE, CINAHL, and LILACS electronic databases. The original systematic review conducted a search between 1990 and April 2014; we updated the original search strategy, with minor modifications, and ran the search from April 2014 to November 2019. A combination of MeSH and keyword terms on the topics of immunization and missed opportunities for vaccination were used (full search strategy available upon request).

Rate of MOVs in Latin America (Objective 2). We included all studies developed by the Comprehensive Family Immunization Unit of the Family, Health Promotion and Life Course Department of PAHO, which were retrieved by one author (MV), an advisor in the department.

Gray literature. Relevant researchers and organizations (WHO, PAHO, UNICEF) were contacted to retrieve any additional material for both Objective 1 and 2.

Reference lists. We reviewed reference lists of relevant citations to retrieve any additional study meeting our eligibility criteria for Objectives 1 and 2.

Data collection and analysis (Objective 1)

Selection of studies. We used a pretested form to select studies meeting eligibility criteria. After removing duplicate results, we screened titles/abstracts and full-text articles (authors MT and RB) in succession. We consulted a third author (ACL) to resolve disagreements.

Data abstraction and management. Data abstraction was conducted independently and in duplicate by authors (MT, RB, ACL) using a pretested form. We abstracted study characteristics (author, country, journal of publication, year of publication) in addition to data on included populations, interventions, comparisons, and outcomes of interest. We contacted corresponding authors for clarification when needed.

Risk of bias assessment. We (MT, RB) independently and in duplicate assessed risk of bias for which we used the Cochrane Risk of Bias tool for randomized clinical trials, and suggested risk of bias criteria for non-randomized studies by the Cochrane Effective Practice and Organization of Care group (20).

Data synthesis. When criteria for pooling results were met (the population, intervention, and comparator were judged to be similar enough across studies), we conducted meta-analysis in Review Manager 5.3 to calculate summary estimates. We used a frequentist approach and random-effects models to account for potential, unexplained heterogeneity between studies. We used the participants or clinic visits as the unit of analysis. When it was not possible to conduct meta-analysis (e.g., important clinical heterogeneity precluded us from conducting a meta-analysis), we reported results narratively. We also accounted for differences in study design and synthesized data separately for RCTs and non-randomized studies. For each comparison, we reported any pooled estimates at an outcome level as risk ratios (RR) or odds ratios (OR) in Grading of Recommendations Assessment, Development and Evaluation (GRADE) Summary of Findings Tables (21). We used the event rate of the control groups to estimate the baseline risk of associated outcomes and obtain absolute estimates of effect.

Assessment of certainty of the evidence. The certainty of the evidence can be rated as high, moderate, low, or very low and is influenced by study design and other domains that can decrease (issues of risk of bias, inconsistency, imprecision, indirectness, and publication bias) or increase the certainty (large magnitude of effect, dose-response gradient, and residual confounding acting opposite to what was observed). We assessed the certainty of the evidence at an outcome level using the using the GRADE approach (22).

Handling of missing data and other analyses. We planned to contact study authors to obtain missing outcome data if such missing data were judged to affect the certainty of the evidence. We did not conduct any subgroup or sensitivity analyses.

Data collection and analysis (Objective 2)

Data abstraction and management. We abstracted data from selected studies using a pretested data abstraction form. We collected information on the country, target population, data collection period, number of included participants and healthcare centers, number of participants eligible for vaccination, number of MOVs, and reasons for MOVs. For studies including child populations, we collected information about caregivers and any other person(s) responsible for making vaccination-related decisions.

Data analysis. When criteria for pooling were not met, we summarized data narratively. When studies included/used similar populations and methodology, we calculated an overall rate of MOVs by pooling the proportion of MOVs across studies using a generalized linear mixed model, implemented using the metaprop package in the software R (23, 24). We assessed the certainty of the evidence using the same methodology detailed above for Objective 1.

RESULTS

How to interpret the results

The GRADE certainty of the evidence reflects how certain we are that the true effect lies within a particular range of results. For example, low certainty evidence implies that the results may be importantly different to what was observed (21). In addition to the certainty of the evidence, interpreting results requires, for example, making a judgment of the importance of the magnitude of reduction in MOVs observed. For example, an absolute risk reduction of 3% of MOVs when providing training to the healthcare team on how to communicate with patients (compared with standard of care) may be too small to be considered important and worth the efforts necessary to
provide such training. Finally, it is important to consider that, although important, MOVs are a surrogate for outcomes that are important to patients, such as prevention of diseases. No included studies measured patient-important outcomes.

Results (Objective 1)

The original electronic search retrieved 469 citations, and the contacted organizations suggested 30 papers. We screened all associated titles and abstracts, and 49 articles in full text. The updated search identified 350 new citations, of which 42 were ultimately full-text screened. A total of 27 studies from both searches met eligibility criteria, 6 of which are from the updated search (25–51). The results of the search and screening process are detailed in a PRISMA flow diagram (Figure 1).

Description of included studies

We included 15 randomized controlled trials (26, 28, 31, 32, 35–39, 41, 43, 45, 48, 49, 51), 2 non-randomized controlled trials (47, 50), 8 before-and-after studies (25, 27, 29, 33, 34, 40, 42, 44, 46), and 1 interrupted time series (30), all published between 1992 and 2019 (study characteristics table available upon request).

Of these studies, 20 were conducted in the United States of America (26, 28–31, 33–37, 41–45, 47–51), 3 in Australia (39, 40, 46), 2 in India (27, 32), 1 in Nigeria (25), and 1 in Sudan (38). No studies were conducted in multiple countries. Fourteen studies were based in a primary care setting (25, 26, 28, 29, 31, 33, 34, 36, 37, 40, 43, 47, 49, 50), 8 in a hospital setting (27, 30, 38, 39, 42, 44–46), 1 in a private clinic (32), and the 3 in a community setting (35, 41, 51). One study was based in both a primary care setting and hospital setting (48).

One study included older adults (39), 1 study children and adolescents with asthma (31), and 1 adolescents (33). Of the remaining studies, 21 included infants or children (25–27, 29, 30, 34–36, 38, 41–43, 46, 47, 49–55), while 3 studies included adults (32, 37, 40), with 1 specifically including pregnant women (32).

Due to the complexity of interventions intended to reduce MOVs, many of the studies reported that the unit of analysis differed from the unit of randomization. Most often researchers randomized practices or physicians and collected and analyzed data at the level of participants or visits. In 10 studies, the unit of intervention was the caregiver or parent of the child (26, 31, 35, 36, 38, 41, 43, 46, 47, 51). Fourteen targeted health workers (27–30, 32, 37, 39, 41, 44–46, 49, 50, 54), 2 both health workers and caregivers (34, 48), 1 targeted adult patients (40), and 3 involved health system and organizational changes (25, 33, 38).

Most included reported estimates of effect associated with the following interventions: improvements in accessibility to vaccination site (38); reminders to healthcare teams (30, 31, 33, 34, 42, 45, 48, 49), patients and caregivers (26, 35, 36); educational interventions for healthcare teams (27, 44, 46, 49), patients and caregivers (40, 47, 51); monetary incentives (28) and fines (41), free vaccination programs (29), exemption from caregiver’s authorization (48), patient tracking (43), provider training on communication with patients (37), recommendations provided

FIGURE 1. PRISMA flow chart

Source: Prepared by the authors based on the results from this review.
by clinicians (32), quality improvement programs (25), and pharmacist presence (50).

There were significant variations in how the primary outcome of interest, reduction in MOVs, was measured. Some studies reported MOVs per patient per year (48), while others reported MOVs for specific vaccines (41), the number of visits at which MOVs occurred (45), mean number of MOVs per infant (47), captured opportunities (i.e., opposite of MOV) (31), and/or opportunistic immunizations (i.e., opportunities that would have been missed) (46).

**Risk of bias assessments**

Major issues of risk of bias were observed in 15 RCTs (risk of bias assessments available upon request); these included issues related to random sequence generation and allocation concealment. Eight RCTs were judged as having unclear or high risk of bias due to issues with random sequence generation (28, 31, 32, 35–37, 39, 41, 48, 49, 51), and 8 RCTs were judged to have unclear or high risk of bias due to issues with allocation concealment (26, 31, 38, 39, 41, 45, 48, 51). Two non-randomized controlled trials (47, 50) and 9 before-and-after studies (25, 27, 29, 33, 34, 40, 42, 44, 46) were at high risk of bias due to issues with random sequence generation. Finally, 22 out of the 27 included studies were judged to have unclear or high risk of bias due to incomplete or missing outcome data (25–27, 29, 31, 33–37, 39, 40, 42–51).

We summarized the effect of interventions for reducing MOVs and the certainty of this evidence in Table 1. Most studies compared interventions to standard of care (or to no intervention).

**TABLE 1. Summary of findings on interventions to reduce missed opportunities for vaccination**

| Intervention | Study design (number of studies) | Relative risk (95% confidence interval), OR (95% confidence interval), or range in point estimates | Absolute risk reduction (95% CI) (how many fewer MOVs) | GRADE certainty of evidence | Interpretation |
|--------------|---------------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------------------|----------------|
| **Interventions aimed at healthcare team** | | | | | |
| Reminders attached to medical records | RCT (3) | 0.50 (0.19, 1.33) | 245 fewer per 1 000 patients (397 fewer to 162 more) | LOW | There may be a reduction in MOVs. |
| Educational interventions and performance feedback | OS (4) | RR ranged from 0.54 to 0.96 | RR ranged from 20 to 36 fewer per 1 000 patients | LOW | There may be a reduction in MOVs. |
| | OS (3) | 0.27 (0.20, 0.36) at participant level | 359 fewer per 1 000 patients (393 fewer to 315 fewer) | LOW | There may be a reduction in MOVs. |
| | | 0.56 (0.35, 0.88) at visit level | 128 fewer per 1 000 patients (190 fewer to 350 fewer) | LOW | There may be a reduction in MOVs, |
| | Web-based training | RCT (1) | NR | NR | -- | -- |
| | Monetary incentives | RCT (1) | NR | 7.5% of MOVs were reduced with bonus check | MODERATE | There is probably a reduction in MOVs. |
| | Training on how to communicate with patients | RCT (1) | 0.97 (0.95, 0.98) | NE | MODERATE | There is probably a reduction in MOVs. |
| | Provision of expert recommendations | RCT (1) | NR | NR | -- | -- |
| **Interventions aimed at patients or caregivers** | | | | | |
| | Reminders and alerts (mailed and telephone calls) | RCT (3) | 1.36 (0.67, 2.77) | 112 more per 1 000 patients (102 fewer to 549 more) | VERY LOW | We are very uncertain about the effect. |
| | Reminders (SMS) | RCT (1) | 0.7 (0.48, 1.01) | NE | VERY LOW | We are very uncertain about the effect. |
| | Educational interventions | RCT (1) | 0.89 (0.73, 1.09) | 59 fewer per 1 000 patients (144 fewer to 48 more) | MODERATE | There is probably a small to no reduction in MOVs. |
| | | Non RCT (1) | 0.50 (0.34, 0.74) | 179 fewer per 1 000 patients (930 fewer to 237 fewer) | VERY LOW | We are very uncertain about the effect. |
| | Monetary fines | RCT (1) | 0.87 (0.80, 0.94) | 560 fewer per 1 000 patients (860 fewer to 160 fewer) | LOW | There may be a reduction in MOVs. |
| | Patient tracking and outreach | RCT (1) | NR | NR | -- | -- |
| **Interventions aimed at the healthcare system** | | | | | |
| | Improvement in accessibility (more visible vaccination area) | RCT (1) | NR | NR | -- | -- |
| | Free vaccination program | OS (1) | 1.00 (0.95, 1.05) | 0 fewer per 1 000 (300 fewer to 300 more) | LOW | There may be little to no effect on MOVs. |
| | Exemption from authorization | RCT (1) | NR | Researchers describe no statistical differences between the groups | LOW | There may be little to no effect on MOVs. |
| | Quality improvement program | OS (1) | NR | NR | VERY LOW | We are very uncertain about the effect. |
| | Presence of pharmacist | Non RCT (1) | OR 0.56 (0.35, 0.90) | 46 fewer per 1 000 patients (70 fewer to 10 fewer) | LOW | There may be a reduction in MOVs. |

**Source:** Prepared by the authors based on the results from this review.

**Notes:** MOV, missed opportunity for vaccination; RCT, randomized controlled trial; OS, observational study; RR, risk ratio; NR, not reported; NE, not estimable; OR, odds ratio.
The study characteristics table (available upon request) details all comparisons.

**Interventions targeting healthcare team**

Eight studies identified interventions targeting the healthcare team. There was moderate certainty evidence that monetary incentives (7.5% reduction in MOVs) (29) and training on how to communicate with patients (RR 0.97; 95% CI [0.95, 0.98]) (37) probably reduce MOVs. There was low certainty evidence suggesting that reminders attached to medical records (RR 0.50; 95% CI [0.19, 1.33] from RCTs) (38) may reduce MOVs, that educational interventions and performance feedback may reduce MOVs (RR 0.27; 95% CI [0.20, 0.36]), and that educational interventions may reduce MOVs (RR 0.56; 95% CI [0.35, 0.88]) (27, 44, 46). One study on web-based training (49) and another using provision of expert recommendations (32) did not report reductions in MOVs.

**Interventions targeting patients or caregivers**

Seven studies identified interventions targeting patients or caregivers. There was moderate certainty evidence that educational interventions likely reduce MOVs (RR 0.89; 95% CI [0.73, 1.09]) (51). There was low certainty evidence suggesting that monetary fines may reduce MOVs (RR 0.87; 95% CI [0.80, 0.94]) (41). The certainty of evidence was very low for reminders and alerts, either mailed or by telephone (26, 35, 36), and SMS (short message service) (40). One study assessed patient tracking and outreach for reducing MOVs, but no estimates could be abstracted (43).

**Interventions targeting the healthcare system**

Five studies identified interventions targeting healthcare systems. There was low certainty evidence suggesting that presence of a pharmacist (OR 0.56; 95% CI [0.35, 0.90]) (50), offering free vaccination programs (RR 1.00; 95% CI [0.95, 1.05]) (29), and exempting patients from caregiver authorization (researchers reported no statistical differences) may reduce MOVs (48). There was very low certainty evidence suggesting that quality improvement programming may result in little to no reduction of MOVs (no reduction reported) (25). One study measuring outcomes of improving accessibility to vaccination sites did not report reduction of MOVs (38).

**Results of studies developed by PAHO (Objective 2)**

We included five studies conducted between 2012 and 2018 in Honduras, Ecuador, Peru, Panama, and Bogotá (Colombia) (52–56). Studies included 368 to 2 495 participants. Three of the studies focused on reducing MOVs in children under 5 years of age (52, 53, 55), one on children under 3 (54), and another on children under 2 years (56). All studies used a cross-sectional design, and one added a qualitative design component (52). Table 2 summarizes the main characteristics of these studies.

Studies reported a total of 579 MOVs for 2 030 children eligible for vaccination (a rate of 5%–37% MOVs per country) (Table 2). The pooled rate of MOVs, estimated from data from five countries in the Region, was 17% (95% CI [9, 32]). Statistical tests suggest important heterogeneity among included studies (F 97%). All studies reported that parents/caregivers, primarily women, made vaccination-related decisions for their children, and MOVs did not seem to be associated with the caregiver’s level of education (32%–72% of caregivers completed high school) (Table 2). The reasons for MOVs varied across countries, and the largest proportion of MOVs were attributable to healthcare personnel knowledge, attitudes, and practices (Figure 2).

**Certainty of the evidence for Objectives 1 and 2**

The certainty of the evidence on interventions for reducing MOVs ranged from very low to moderate certainty, due to serious issues of risk of bias and imprecision, and studies measuring the prevalence of MOVs in Latin America were of low certainty. The main limitation of this second body of evidence was indirectness (applicability concerns) and imprecision, with the extremes of the confidence interval of the pooled estimate suggesting a small prevalence of MOVs at one extreme and a large prevalence of MOVs at the other.

**DISCUSSION**

This review summarizes the proportion of MOVs in the Region and the best available evidence on interventions (targeting healthcare teams, patients or caregivers, and healthcare systems) for reducing MOVs. Results from studies from the Region suggest that 17% of recommended vaccines are missed (low certainty evidence). Results also suggest that monetary

| Country | Target population | Number of caregivers interviewed | Sex (% girls) | Attending healthcare center for vaccination | MOVs (95% CI) | % caregivers with education higher than high school | % caregivers that at least completed high school |
|---------|------------------|---------------------------------|---------------|------------------------------------------|---------------|-----------------------------------------------|-----------------------------------------------|
| Colombia | <2 years         | 738                             | 52%           | 43%                                      | 5% (2.12)     | -30%                                          | -70%                                          |
| Honduras | <5 years         | 696                             | 51%           | 54%                                      | 9% (6.12)     | 6%                                            | 32%                                           |
| Panama  | <5 years         | 1,139                           | 51%           | 23%                                      | 17% (14.21)   | 25%                                           | 53%                                           |
| Ecuador | <5 years         | 368                             | NR            | 50%                                      | 36% (27.45)   | 43%                                           | 72%                                           |
| Peru    | <5 years         | 2,495                           | 50%           | 26%                                      | 37% (34.40)   | 26%                                           | 67%                                           |

*Source:* Prepared by the authors based on the results from this review.

*Notes:* MOV, missed opportunity for vaccination; NR, not reported.
incentives to healthcare teams, training healthcare teams on patient communication, and educational interventions for caregivers probably reduce MOVs (moderate to very low certainty across interventions and outcomes).

Overall completeness and applicability of evidence

For our first research objective, reports meeting eligibility criteria studied interventions for reducing MOVs for children and were conducted in Australia and the United States of America—countries with high vaccine coverage. This may limit the applicability of the findings to adults or settings in low- and middle-income countries, including several countries within the Region. Although there was a variety of included interventions, which readers might interpret as increased applicability, each of the interventions seemed to have its own unique effect. Because of this, the effect of a specific intervention should not be generalized to other interventions aimed at the same recipient. Cross-sectional studies on the prevalence of MOVs in Latin America were conducted in five countries. The heterogeneity observed among these studies decreases the applicability of the findings to settings outside of the Region.

Agreement and disagreement with other studies or reviews

In a recently published systematic review, authors addressed our first research objective (13). In comparison, we did not limit eligibility criteria to RCTs (resulting in 26 additional studies added to this review), performed more comprehensive searches, and evaluated certainty of the evidence using the GRADE approach; this allowed us to more accurately present limitations that may influence results and conclusions. Finally, authors from the previous review suggested that patient education/tracking, outreach sessions, and provider prompts reduced MOVs. Our review suggests that, in addition to the interventions suggested by the previous review, monetary incentives for healthcare teams probably reduce MOVs.

Implications for research

We suggest the development of higher-quality randomized and non-randomized studies on interventions for reducing MOVs, especially for adult and special populations that require vaccination (e.g., women of childbearing age and seniors). We also suggest that this research be conducted in low- or middle-income countries (or those with lower vaccination coverage) and in the context of issues associated with access to care, vaccine hesitancy, and the COVID-19 pandemic. We encourage testing of cross-cutting health system changes, interventions targeting vaccine hesitancy, and community-level interventions. Furthermore, we encourage reporting of outcomes such as costs, vaccine wastage rate, satisfaction with care, occurrence of vaccine-preventable diseases, and healthcare personnel’s attitudes. In addition, uniform definitions of MOVs should be adopted to promote comparability of studies.

Implications for practice and policy

The results of this review suggest an important rate of MOVs in the Region. This is in line with evidence on decreased vaccine coverage, weakening of epidemiological surveillance, emerging outbreaks of vaccine-preventable diseases, inadequate long-term sustainable financing, the challenge of scientific misinformation, and increasing vaccine hesitancy. Every effort must be made to consider interventions for reducing MOVs while maintaining the trust of populations in the Region in vaccination services, establish and follow national guidelines for immunization in the context of COVID-19 transmission, prioritize newborn vaccinations, and maintain periodic and systematic registries of the population pending vaccination (7, 57). Now more than ever, ensuring that every child who accesses a health center has their vaccination status reviewed and their vaccination schedule completed will be an opportunity to improve vaccination coverage and reduce incidence of vaccine-preventable diseases (1).

Strengths and limitations of this review

The strengths of this review include not limiting evidence to studies in English, assessment of gray literature, and conducting screening and data abstraction independently and in duplicate. This review is limited by reporting issues in and methodological quality of the included evidence, which largely prevented us from conducting meta-analyses or from presenting the results in a consistent manner across interventions/outcomes. Furthermore, a paucity (and poor reporting) of study data resulted in our analysis not comprehensively accounting for instances where unit of randomization differed from unit of analysis. This may have resulted in confidence intervals that are more precise than they should be. Because the certainty of many of our estimates was rated down for imprecision, we believe that unit of analysis issues did not have an important impact on our conclusions.

Conclusion

MOVs can increase the incidence of vaccine-preventable diseases in the Region. Clinicians and other decisionmakers within the Region should consider this review’s limitations, paucity of
evidence on patient-important outcomes, and the influence of several other factors (including costs, feasibility, acceptability, and equity) before implementing interventions for reducing MOVs (monetary incentives to healthcare teams, training healthcare teams on patient communication, and educational interventions for caregivers) at an individual or population level.

**Author contributions.** MV conceived the original project idea. All authors (MT, ACL, KB, MV, RB) contributed to the planning, data collection, and analysis as well as writing, reviewing, and approving the final version of the manuscript.

**Acknowledgments.** The authors would like to thank the national officials, subnational authorities, local health workers, and parents in Colombia, Ecuador, Honduras, Panama, and Peru for their participation in these assessments of missed opportunities for vaccination. Without the cooperation and collaboration of all of them, including officers of the Pan American Health Organization and the Albert B. Sabin Institute (Grant 397020 Improving Vaccine Coverage Rates in the Latin American Region), this review would not have been successfully completed.

**Conflict of interest.** The authors declare no conflict of interest, including financial ties, academic commitments, personal relationships, political or religious beliefs, and institutional affiliation, among others.

**Financial support.** This study was funded by the Pan American Health Organization.

**Disclaimer.** Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or those of the Pan American Health Organization.

**REFERENCES**

1. World Health Organization [Internet]. Geneva: WHO; 2021. Vaccines and immunization. Available from: http://www.who.int/topics/immunization/en/.
2. World Health Organization [Internet]. Geneva: WHO; 2021. Immunization coverage 2014. Available from: http://www.who.int/mediacentre/factsheets/fs378/en/.
3. Llau A. National vaccine coverage trends and funding in Latin America and the Caribbean. Vaccine 2021;39:317–23.
4. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Immunization myths and realities: responding to arguments against immunization. J Paediatr Child Health. 2003;39(7):487–91.
5. MacIntyre CR, Leask J. Immunization myths and realities: responding to arguments against immunization. J Paediatr Child Health. 2003;39(7):487–91.
6. Pan American Health Organization [Internet]. Washington, DC: PAHO; 2016. Region of the Americas is declared free of measles. Available from: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=12528:region-americas-declared-free-measles&Itemid=1926&lang=en
7. Pan American Health Organization. Annual Report of the Director of the Pan American Sanitary Bureau 2020. Saving Lives and Improving Health and Well-Being, Washington, DC: PAHO; 2020. Available from: https://iris.paho.org/handle/10665.2/52852
8. Viechtbauer W. Conducting Meta-Analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.
9. Favin M, Steinglass R, Fields R, Banerjee K, Sawhney M. Why children are not vaccinated: a review of the grey literature. Int Health. 2012;4(4):229–38.
10. Schunemann HJ, Cuello C, Akil EA, Mustafa RA, Meerpohl JJ, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105–14.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.
12. Nogueira-Rodrigues A. HPV Vaccination in Latin America: Global Challenges and Feasible Solutions. Am Soc Clin Oncol Educ Book. 2019;e45–e52.
13. Organización Panamericana de la Salud. Metodología para la evaluación de oportunidades perdidas de vacunación. Washington, DC: OPS; 2014.
14. Cochrane Effective Practice and Organisation of Care. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. Available from: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors
15. Guyatt G, Oxman AD, Akil EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.
16. Balshem H, Helland M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.
17. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016.
18. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36(3):1–48.
19. Adamu AA, Uthman OA, Gadanya MA, Wiysonge CS. Implementation and evaluation of a collaborative quality improvement program to improve immunization rate and reduce missed opportunities for vaccination in primary health-care facilities: a time series study in Kano, Nigeria. Expert Rev Vaccines. 2019;18(9):969–91.
20. Pragman J, Steiner JF, Kempe A, Beatty BL, Pearson KA, Jones JS, et al. Quality improvement in immunization delivery following an unsuccessful immunization recall. Ambul Pediatr. 2004;4(3):217–23.
21. Deivanayagam N, Nedunchelian K, Mala N, Ashok TP, Rathnam SR, Ahmed SS. Missed opportunities for immunization in children under 2 years attending an urban teaching hospital. Indian Pediatr. 1995;32(1):51–7.
22. Fairbrother G, Hanson KL, Friedman S, Butts GC. The impact of physician bonuses, enhanced fees, and feedback on childhood immunization coverage rates. Am J Public Health. 1999;89(2):171–5.
29. Fairbrother G, Friedman S, Hanson KL, Butts GC. Effect of the vaccines for children program on inner-city neighborhood physicians. Arch Pediatr Adolesc Med. 1997;151(12):1229–35.

30. Fiks AG, Grundmeier RW, Biggs LM, Localio AR, Alessandri EA. Impact of clinical alerts within an electronic health record on routine childhood immunization in an urban pediatric population. Pediatrics. 2007;120(4):707–14.

31. Fiks AG, Hunter KE, Localio AR, Grundmeier RW, Bryant-Stephens T, Luberti AA, et al. Impact of electronic health record-based alerts on influenza vaccination for children with asthma. Pediatrics. 2009;124(1):159–69.

32. Giduthuri JG, Purohit V, Maire N, Kudale A, Utzinger J, Schindler C, et al. Influenza vaccination of pregnant women: Engaging clinicians to reduce missed opportunities for vaccination. Vaccine. 2019;37(14):1910–7.

33. Harper PG, Murray DM. An organizational strategy to improve adolescent measles-mumps-rubella vaccination in a low socioeconomic population. A method to reduce missed opportunities. Arch Fam Med. 1994;3(3):257–62.

34. Hicks P, Tarr GAM, Hicks XP. Reminder cards and immunization rates among Latinos and the rural poor in Northeast Colorado. J Am Board Fam Med. 2007;20(6):581–6.

35. Irgoyen MM, Findlay S, Wang D, Chen S, Chimkin F, Pena O, et al. Challenges and successes of immunization registry reminders at inner-city practices. Ambul Pediatr. 2006;6(2):100–4.

36. Kempe A, Lowery NE, Pearson KA, Renfrew BL, Jones JS, Steiner JE, et al. Immunization recall: effectiveness and barriers to success in an urban teaching clinic. J Pediatr. 2001;139(5):630–5.

37. Lin CJ, Nowalk MP, Pavlik VN, Brown AE, Zhang S, Raviotta JM, et al. Using the 4 pillars™ practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial. BMC Infect Dis. 2016;16(1):623.

38. Loevinsohn BP, Gareaballah E. Missed opportunities for immunization during visits for curative care: a randomized cross-over trial in Sudan. Bull World Health Organ. 1992;70(3):335–9.

39. MacIntyre CR, Kainer MA, Brown GV. A randomised, clinical trial comparing the effectiveness of hospital and community-based reminder systems for increasing uptake of influenza and pneumococcal vaccine in hospitalised patients aged 65 years and over. Gerontology. 2003;49(1):33–40.

40. McIver R, Dyda A, McNulty AM, Knight V, Wand HC, Guy RJ. Text messages with reminders do not improve hepatitis B vaccination rates and reduce missed opportunities. Arch Pediatr Adolesc Med. 1999;153(12):1242–7.

41. Martinez Reyes IE, Varela Murillo MI, Sevilla Maradiaga JI, Estrada OM, McField Montes GJ, Pardo Cruz F, et al. Oportunidades Perdidas de Vacunación en los niños menores de cinco años en los Establecimientos de Salud del Primer Nivel de Atención, Honduras, mayo del 2018. Tegucigalpa: Gobierno de la República de Honduras, Secretaría de Salud; 2018.

42. Minkovitz CS, Holt E, Hughart N, Hou W, Thomas L, Dini E, et al. Reducing missed opportunities for immunizations. Easier said than done. Arch Pediatr Adolesc Med. 1996;150(11):1193–200.

43. Minkovitz CS, Belote AD, Higman SM, Serwint JR, Weiner JP. Evaluating the potential for opportunistic vaccination in a Northern Territory hospital. J Paediatr Child Health. 1999;35(5):472–5.

44. Sabnis SS, Pomeranz AJ, Amateau MM. The effect of education, feedback, and provider prompts on the rate of missed vaccine opportunities in a community health center. Clin Pediatr (Phila). 2003;42(2):147–51.

45. Shaw JS, Samuels RC, Larusso EM, Bernstein HH, Rodewald LE, Szilagyi PG, et al. Impact of an encounter-based prompting system on resident vaccine administration performance and immunization knowledge. A randomized study of tracking with outreach and provider prompting to improve immunization coverage and primary care. Pediatrics. 2000;105(4 Pt 2):978–83.

46. Skull S, Krause V, Roberts L, Dalton C. Evaluating the potential for opportunistic vaccination in a Northern Territory hospital. J Paediatr Child Health. 1999;35(5):472–5.

47. Stille CJ, Christison-Lagay J, Bernstein BA, Dworkin PH. A simple provider-based educational intervention to boost infant immunization rates: a controlled trial. Clin Pediatr (Phila). 2001;40(7):365–73.

48. Szilagyi PG, Rodewald LE, Humiston SG, Pollard L, Klossner K, Jones AM, et al. Reducing missed opportunities for immunizations. Easier said than done. Arch Pediatr Adolesc Med. 1996;150(11):1193–200.

49. Werk LN, Diaz MC, Cadilla A, Franciosi JP, Hossain MJ. Promoting Adherence to Influenza Vaccination Recommendations in Pediatric Practice. J Prim Care Community Health. 2019;10:2150132719853061.

50. Wise KA, Sebastian SJ, Haas-Gehres AC, Moore-Clingenpeel MD, Lamberjack KE. Pharmacist impact on pediatric vaccination errors and missed opportunities in the setting of clinical decision support. J Am Pharm Assoc. 2017;57(3):356–61.

51. Wood D, Schuster M, Donald-Sherbourne C, Duan N, Mazel R, Halton N. Reducing missed opportunities to vaccinate during child health visits. How effective are parent education and case management? Arch Pediatr Adolesc Med. 1998;152(3):238–43.

52. Martínez Reyes IE, Varela Murillo MI, Sevilla Maradiaga JI, Estrada OM, McField Montes GJ, Pardo Cruz F, et al. Oportunidades Perdidas de Vacunación en los niños menores de cinco años en los Establecimientos de Salud del Primer Nivel de Atención, Honduras, mayo del 2018. Tegucigalpa: Gobierno de la República de Honduras, Secretaría de Salud; 2018.

53. Jimbo Sotomayor R, Armijos Acuario L, Sánchez Choez X, Vilema Ortiz M, Ghisays G, Moyota Quinzo D, et al. Missed opportunities of vaccination in primary health care establishments in Ecuador. Vacunas. 2019;20(2):46–52.

54. Perú, Ministerio de Salud; Organización Panamericana de la Salud. Investigación de oportunidades perdidas para vacunación (OPPV) en Perú. [Report acquired through the Pan American Health Organization Comprehensive Family Immunization Unit.] Perú, Ministerio de Salud; 2014.

55. Quiroz N, Jimeno J, Sales V, Alvarez S, Fossatti L. Informe Final: Oportunidades Perdidas de Vacunación en Colombia, Organización Panamericana de la Salud; 2014.

56. Sigma Dos Colombia; Organización Panamericana de la Salud. Evaluación de oportunidades perdidas de vacunación en la República de Panamá. [Report acquired through the Pan American Health Organization Comprehensive Family Immunization Unit.] Panama City: Vax Trials; 2014.

57. Sigma Dos Colombia; Organización Panamericana de la Salud. Evaluación de oportunidades perdidas de vacunación en Colombia. [Report acquired through the Pan American Health Organization Comprehensive Family Immunization Unit.] Bogotá: Sigma Dos Colombia, Organización Panamericana de la Salud; 2014.

58. MacDonald N, Molsni E, Al-Mazrou Y, Andrus JK, Arora N, Elden S, et al. Global vaccine action plan lessons learned I: Recommendations for the next decade. Vaccine. 2020;38(33):5364–71.

Manuscript submitted on 14 July 2021. Revised version accepted for publication on 24 November 2021.
Resumen

Objetivos. Estimar la prevalencia de las oportunidades perdidas de vacunación en América Latina y el efecto de las intervenciones dirigidas a los sistemas de salud, los trabajadores de salud, los pacientes y las comunidades.

Métodos. Se realizaron búsquedas en las bases de datos electrónicas MEDLINE, EMBASE, CINAHL y LILACS y se estableció contacto con las organizaciones pertinentes, incluida la Organización Panamericana de la Salud (OPS), para identificar aquellos estudios que cumplieran con los criterios de admisibilidad. Un par de revisores identificaron 27 estudios aleatorizados y no aleatorizados que cuantificaban la efectividad de cualquier intervención para reducir las oportunidades perdidas de vacunación, así como 5 estudios que evaluaban la tasa de oportunidades perdidas de vacunación en América Latina. Cuando no cumplían con los criterios para agrupar los resultados, estos se presentan de manera narrativa; para evaluar la certeza de esta evidencia se utilizó el método GRADE.

Resultados. La evidencia indica que la tasa de oportunidades perdidas de vacunación en América Latina osciló entre 5% y 37% y presentó una estimación consolidada de 17% (IC del 95% [9, 32]) (certeza baja), y que los incentivos monetarios a los equipos de atención médica, la capacitación de los equipos de salud sobre cómo comunicarse con los pacientes y las intervenciones educativas destinadas a los cuidadores probablemente reducen las oportunidades perdidas de vacunación (certeza moderada a muy baja).

Conclusiones. No hay suficiente evidencia para respaldar la aplicación de alguna intervención como política basándose únicamente en la reducción potencial de las oportunidades perdidas de vacunación si no se tienen en cuenta varios factores, como los costos, la viabilidad, la aceptabilidad y la equidad.

Palabras clave. Vacunación; cobertura de vacunación; inmunización; América Latina.

Resumo

Objetivos. Estimar a prevalência de oportunidades perdidas de vacinação (OPV) na América Latina e o efeito de intervenções para reduzir as OPV direcionadas aos sistemas de saúde, profissionais de saúde, pacientes e comunidades.

Métodos. Foi realizada a pesquisa em bancos de dados eletrônicos (MEDLINE, Embase, CINAHL e LILACS) e mediante contato com instituições relevantes, como a Organização Pan-Americana da Saúde (OPAS), com o objetivo de identificar estudos que satisfizessem os critérios de inclusão. Dois revisores identificaram 27 estudos randomizados e não randomizados com avaliação quantitativa da efetividade de intervenções para reduzir as OPV e 5 estudos que avaliavam a taxa de OPV na América Latina. Os resultados foram apresentados de forma descritiva quando não preenchiam os critérios para apresentação conjunta. O sistema GRADE foi usado para avaliar a qualidade das evidências.

Resultados. As evidências indicam que a taxa de OPV na América Latina variou entre 5% e 37%, com uma estimativa conjunta de 17% (IC 95% [9, 32]) (qualidade da evidência: baixa). Incentivos financeiros e capacitação em comunicação com os pacientes para as equipes de saúde, bem como intervenções educacionais para os cuidadores, provavelmente reduzem as OPV (qualidade da evidência: moderada a muito baixa).

Conclusões. Não há evidências suficientes para respaldar implementar qualquer intervenção como política com base somente na possível redução das OPV, sem levar em consideração diversos fatores como custos, viabilidade, aceitabilidade e equidade.

Palavras-chave. Vacinação; cobertura vacinal; imunização; América Latina.